Search the Newsreel

XAIR|Beyond Air Inc|Price:7.160|Chg%:+1.110

Beyond Air (XAIR) Fiscal Q1 2027 Earnings Call: FDA Catalyst, $8M 2026 Outlook

Beyond Air (XAIR) reported stable fiscal Q1 2027 revenue of $1.8 million and improved gross margins of 13%. The company reaffirmed its 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, with the latter contingent on FDA approval …

Beyond Air Inc (XAIR) Earnings Date & Reports & Earnings News

XAIR | Beyond Air, Inc. Common Financials - Revenue Breakdown

Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ...

Beyond Air Inc (XAIR) reported its Q1 2027 earnings, with revenue flat at $1.8 million but an improved gross margin of 13%. The company secured new financing of up to $30 million and expanded its market access with a third national group purchasing agreement, …

Beyond Air (XAIR) posts $7.9M loss and cites funding risk in quarter

Beyond Air (XAIR) reported a net loss of $7.9 million for the quarter ended June 30, 2026, with essentially flat revenue of $1.8 million. The company highlighted substantial doubt about its ability to meet obligations within one year without additional financing, due to recurring …

Beyond Air Releases Q1 2027 Financial Results

Beyond Air (XAIR) reported a Q1 2027 loss of $11.00 per share, missing analyst estimates but showing a significant 64.1% year-over-year improvement from $30.67. The medical technology company, which develops nitric oxide delivery systems, continues to receive a generally positive outlook from Wall Street …

Beyond Air earnings missed by $0.10, revenue fell short of estimates

Earnings call transcript: Beyond Air misses Q1 2027 revenue view, shares fall premarket

Beyond Air (XAIR) reported Q1 fiscal 2027 revenue of $1.77 million, missing Wall Street's forecast of $2.21 million, leading to a 7.11% premarket stock decline. Despite the revenue miss and a net loss of $7.9 million, the company showed positive gross profit for the …

Beyond Air Q1 FY27 net loss widens to $8.15 million; revenue flat at $1.77 million

Beyond Air Reports $1.8 Million Q2 Revenue, Reaffirms 2026 and 2027 Guidance as FDA Reviews Second-Generation LungFit PH System

Beyond Air Awaits FDA Review With Up to $30.1M for LungFit Launch

Beyond Air (NASDAQ: XAIR) reported $1.8 million in revenue for Q2 2026, consistent with the prior year, alongside a net loss of $7.9 million. The company reaffirmed its 2026 revenue guidance of $8 million and projected $16-18 million for 2027, contingent on FDA approval …

XAIR Q1'26 Earnings: EPS estimate is (10.80) USD

Beyond Air, Inc. (XAIR) is scheduled to announce its Q1'26 earnings on August 13 before the market opens, with results expected at 9:30 AM ET (1:30 PM UTC). Analysts estimate the company will report revenue of $1.93 million and an EPS of ($10.80) for …

Earnings Preview: Beyond Air to Report Financial Results on August 13

Beyond Air (NASDAQ: XAIR) is scheduled to announce its financial results on August 13. Analysts are forecasting an EPS of -$0.17 for the quarter, with revenue estimates ranging from $1.39 million to $1.6 million.

Earnings Preview: Beyond Air to Report Financial Results Post-market on August 13

Beyond Air (NASDAQ: XAIR) is scheduled to announce its quarterly financial results after the market closes on August 13, 2026. Analysts are predicting an EPS of -$0.23 for the quarter, with revenue forecasts ranging from $1.3 million to $1.9 million. The report will provide …

Beyond Air regains Nasdaq compliance after reverse stock split By Investing.com

Beyond Air (NASDAQ:XAIR) has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split. The company previously received a delisting notice and was granted conditional continued listing. Despite its stock being down significantly over the past year, Beyond Air recently …

Beyond Air (NASDAQ: XAIR) regains compliance, faces 1-year Nasdaq monitor

Beyond Air (XAIR) has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split. The company maintained a closing bid price at or above $1.00 for 17 consecutive trading days, satisfying conditions for continued listing on The Nasdaq Capital Market. …

Beyond Air regains Nasdaq bid-price compliance after 1-for-20 reverse split; discretionary monitor imposed

Beyond Air (XAIR) has regained compliance with Nasdaq's $1.00 bid-price rule following a 1-for-20 reverse stock split effected on July 13, 2026. The company maintained a closing bid price of $1.00 or greater for 17 consecutive trading days. Nasdaq has imposed a one-year Discretionary …

Form 8K Beyond Air Inc For: 6 August By Investing.com

This article from Investing.com reports on Beyond Air Inc.'s Form 8K filing for August 6th. The content primarily consists of market data, including various indices, commodities, currencies, and stock performance, but offers no further details on the specific contents of Beyond Air's filing. It …

Beyond Air will webcast results for quarter ended June 30

Beyond Air (NASDAQ: XAIR) is scheduled to report its financial results for the quarter ended June 30, 2026, on Thursday, August 13, 2026. The company will also host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the …

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

Beyond Air, Inc. (NASDAQ: XAIR) announced that it will report its financial results for the quarter ended June 30, 2026, on Thursday, August 13, 2026. The company will host a conference call and webcast on the same day at 8:00 a.m. Eastern Time to …

Beyond Air (XAIR) CFO Daniel Moorhead Purchases 4,340 Shares

Beyond Air (XAIR) CFO Daniel Moorhead recently purchased 4,340 shares of the company's stock at $5.76 per share, indicating strong insider confidence. While this insider buying is a positive signal, particularly given the absence of insider sales, GuruFocus designates the stock as a "Possible …

Beyond Air, Inc. (XAIR) CEO buys stock plus FDA-linked Series A and B warrants

Beyond Air, Inc.'s CEO, Robert Scott Goodman, purchased 34,722 shares of common stock and an equal number of Series A and Series B Warrants. The warrants are immediately exercisable, with Series A warrants expiring one year after issuance or 45 days post-FDA approval of …

Beyond Air (XAIR) CFO purchases common stock plus Series A and B Warrants

Beyond Air (XAIR) CFO Daniel J. Moorhead reported the purchase of 4,340 shares of common stock at $5.76 per share, along with 4,340 Series A Warrants and 4,340 Series B Warrants, all exercisable for common stock at $5.51 per share. The Series A Warrants …

Beyond Air CFO Daniel Moorhead buys $24,998 in company stock

Beyond Air (NASDAQ:XAIR) CFO Daniel J. Moorhead recently purchased 4,340 shares of the company's common stock for $24,998, along with Series A and Series B Warrants. The purchase occurred when the stock was near its 52-week low and is considered undervalued by InvestingPro analysis. …

Form 4 Beyond Air Inc For: 31 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Beyond Air Inc, dated July 31st. It briefly mentions the stock symbol XAIR and its recent performance, indicating a -2.68% change. The content primarily serves as a placeholder for a financial news item …

Beyond Air Raises $10.2 Million in At-the-Market Priced Private Placement of Stock and Warrants

Beyond Air (XAIR) has successfully raised approximately $10.2 million through an at-the-market priced private placement. The placement involved issuing common shares and warrants to institutional investors and company insiders, with pricing set under Nasdaq rules. The proceeds are intended for working capital and general …

Press Release: Beyond Air(R) Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Beyond Air (NASDAQ: XAIR) has announced a private placement offering of up to $30.1 million. The offering includes common stock and warrants, priced at-the-market under Nasdaq rules, with participants like Avidity Partners and Stonepine Capital. The capital infusion is expected to support the company's …

FDA Approval Would Start a 45-Day Clock on Beyond Air Warrants

Beyond Air (NASDAQ: XAIR) has announced a private placement offering that could generate up to $30.1 million, with an initial $10.2 million upfront. The financing includes common stock and warrants, with Series A warrants having an expiration tied to FDA approval of LungFit II, …

Beyond Air Inc (XAIR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Beyond Air Inc (XAIR), highlighting its current valuation score of 9.53 within the Healthcare Equipment & Supplies industry. It details the company's P/E ratio, noting it is significantly below its recent high but above its recent low. …

XAIR|Beyond Air Inc|Price:5.450|Chg%:-0.010

Beyond Air Inc (XAIR) maintains stable fundamentals with significant growth potential, although its current valuation is considered fair. Analysts have given it "Buy" ratings, with a high target price of $140.00, suggesting an upward trend in the medium term. Despite strong recent market performance, …

Beyond Air Inc (XAIR) Income Statement

This article provides the quarterly and annual income statements for Beyond Air Inc (XAIR), offering detailed financial data on revenue, expenses, and net income. It also includes an FAQ section to help users understand how to interpret various metrics within the income statement. The …

Beyond Air, Inc. Revenue Breakdown – NASDAQ:XAIR